Vertex Pharmaceuticals News

Drug stocks retreated with the broader market Tuesday, while shares of Biogen Idec slipped on news that Chief Executive Officer James Mullen plans to retire from the company later this year.

Shares of Vertex Pharmaceuticals Inc. fell Tuesday after a Wedbush Securities analyst issued a downgrade, citing valuation and limited upcoming catalysts.

Here's the problem with every promising new drug that pops out of a lab: There are a million ways to fail before any treatment completes the testing and clinical trials required for commercial approval.

Leaders of the nonprofit startup Progressive Business Leaders Network realize that fundraising in this economy is tricky.

Vertex Pharmaceuticals Inc. has appointed Nancy J. Wysenski as executive vice president and chief commercial officer.

Boston, MA, -- Smokefree Innotec, Inc. ; Vertex Pharmaceuticals Incorporated TheWallStreetLeader.com is part of Stock Profiler.US, LLC's News Division.

Vertex Pharmaceuticals Incorporated today announced the appointment of Nancy J. Wysenski as Executive Vice President and Chief Commercial Officer.

The nation's largest lender gained more than 3 percent in Germany as the move to pay down debt helped free the bank from restrictions on executive pay that had hampered its search for a new leader.

Vertex Pharmaceuticals is addicted to two things -- spending money and raising the same.

Vertex Pharmaceuticals Incorporated today announced that it has entered into an agreement to sell 11,500,000 shares of its common stock in an underwritten offering at a price to the public of $38.50 per share, which would result in aggregate gross proceeds of $442.8 million.

Vertex Pharmaceuticals Inc. says it intends to offer 10 million shares of its common stock in an underwritten public offering.

It's quite an exciting time to be involved with casino operator MGM Mirage . After $8.5 billion and much hand-wringing , the company is getting set to open its massive CityCenter project, a 67-acre complex which the company hopes will help reduce its $13 billion in debt and drive it forward in a postrecession world.

Xconomy.com -- The liver is hot in the biotech world. Cambridge, MA-based Vertex Pharmaceuticals has made headlines this year with an antiviral drug that it hopes will do for hepatitis Ca 'a chronic liver-damaging condition affecting millions of peoplea 'what a previous generation of treatments did for HIV.

When Nina Dudnik arrived at Harvard Medical School in 2001 to pursue her doctorate, her eyes weren't drawn to the marble hallways, the state-of-the-art facilities, or the august faculty.

WHEATON, Ill.-- --First Trust/Aberdeen Global Opportunity Income Fund has declared the Fund's regularly scheduled monthly common share distribution payable... WHEATON, Ill.-- --First Trust/FIDAC Mortgage Income Fund has declared the Fund's regularly scheduled monthly common share distribution payable on December... WHEATON, Ill.-- --First ...

If you only look at its performance so far this year, Ivy Science & Technology, which has $1 billion in assets, doesn't look terribly impressive.

ARLINGTON, Va.-- --The Consumer Electronics Association today announced that Dr.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/10/09, Teva Pharmaceutical Industries Ltd.

Holders of Vertex Pharmaceuticals Inc.'s 2013 convertible senior subordinated notes have agreed to trade about $109 million worth for about 4.8 million shares of Vertex common stock - about 140,000 shares more than the number of shares promised via the notes, the company announced today.

Drug developer Vertex Pharmaceuticals Inc. said Wednesday that holders of $109 million in convertible notes due in 2013 have agreed to swap the notes for about 4.8 million shares of common stock.